AstraZeneca Results Presentation Deck
12
Capital allocation
Capital allocation strategy unchanged
Reinvestment in the business
|
Free cashflow post-Capex
Maintain a
strong
investment-
grade credit
rating
CEO Opening Remarks
Value-
enhancing
business
development
CAPEX = capital expenditure; YTD = year-to-date.
Progressive
dividend
policy
Priority remains reinvesting in our business
Financial Results
ā
Oncology
BioPharmaceuticals
Rare Disease
CEO Closing Remarks
Investments to drive future growth
Currently >120 projects in Phase II/III development
Investments behind launches in new indications and
strengthening leadership in existing therapy areas
Continued investments in new technologies and
platforms including cell and gene therapies
Value accretive deals
Continue to leverage partnerships to drive innovation
and bring medicines to markets quicker
>20 new approvals in major markets YTDView entire presentation